Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
about
Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceLong-term efficacy and safety of raltegravir in the management of HIV infection.Approved Antiviral Drugs over the Past 50 YearsDolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trialsResistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitorsDolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kineticsHistone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapyAn Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial TherapyTherapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical TrialsHIV-1 drug resistance and resistance testing.What's new for antiretroviral treatment in women with HIVHIV integrase inhibitors: a new era in the treatment of HIV.Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzeeClinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood ProductsSingle and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.Dolutegravir: clinical efficacy and role in HIV therapy.Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Tribute to Mark WainbergCost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsDolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studyResistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasmaEffects of boceprevir and telaprevir on the pharmacokinetics of dolutegravirHIV-associated lipodystrophy: impact of antiretroviral therapy.Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionLong-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.What if HIV were unable to develop resistance against a new therapeutic agent?Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.The role of dolutegravir in the management of HIV infectionA consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.
P2860
Q26799712-BE3F1393-512E-43EA-B3FE-BDEA1F984D7EQ26801286-CA2DBA9B-7AA5-40C6-BEC9-53EE937F956DQ27686870-26DD81F7-74D2-46B8-9945-346416F2803EQ27755387-78F48C81-FD73-430E-9DCE-A72965607D6EQ28077053-15A83648-4FF8-42A3-A104-980DC7F815EFQ28533830-2E0E2A10-8F0A-4DA9-848C-8BD99CB02D16Q28534464-E87BC1F7-6EA1-45D5-868B-9398EFCC7169Q28537694-0CFB5772-E1A4-42DB-B862-B2BEB4AECC2AQ28541754-A3A37DDE-64A9-449F-ADC3-E18F62FBF9CAQ28552210-998BC1A5-6B91-41C2-BF70-09EAD48EC2A6Q28553571-7EA9E941-054B-40AE-A52C-F339CB40E50EQ30245693-59EEF7C3-28E3-4D40-B203-C384B43B905CQ30391322-FC147B60-9B9E-4090-A7ED-B58701CA3E47Q30956943-CE6411DE-96BA-4920-8321-265E9BFB8ABBQ33442370-B5DAE3E5-954F-4EA5-91B0-E717BB53B39CQ33668385-5400A77A-7889-41C5-88FA-7DAC62ECF9E4Q33686465-DFBFFBE1-4D71-4541-9593-33FFD091FDC8Q33725024-4015FAB3-730A-4071-87D0-77E185C961D9Q33767281-66FF9E19-F49B-4CC7-8D50-B310B4AAEF07Q33775397-426C6E95-B64F-47E3-8168-C04BC331BEF7Q33846297-382250E8-A67B-462E-9A5A-AF605539DF0CQ33878754-E533BBB2-2E17-401C-8ED8-D66A333C75AEQ33880221-5272C9F7-347D-4147-A3F4-A89A8F8A2036Q33963458-FB9EBDAD-221B-4062-80BE-7ED2D7E48D9CQ34059575-02DBDAF3-EAFE-4623-9152-456C4A5B03D3Q34134900-8A621EF3-8977-4906-8990-4C6E3E93BEFDQ34151623-E8059238-A5AC-41F4-888F-447649576CEAQ34478840-EDB52BBF-E1A8-4715-95F2-F0A1AD08C5BDQ34496927-3D860574-614F-4D32-B84E-96961C3DF7DAQ34570900-B8CB3895-EB4E-48A1-AB52-4F8B8454FFB1Q34655845-DF30B85A-3CB3-43DA-9070-859615C31F98Q34726183-5D041DC2-E9A4-4632-990F-C3D9B92F08A8Q34823275-0E4AD2B3-0D91-4FDF-81E0-130C088749D2Q34976284-D9CDD9F2-67EF-42A1-9F45-19556405A12EQ35021555-0A85CA39-8754-40FB-A36A-442B5A42C710Q35051393-DFB5B2A2-E1E9-42BE-B7CD-696B788C0E6EQ35103606-B4C2A0FF-20EA-46BD-9CF4-B35F0B934AF6Q35121450-CE289BF3-AEC2-4BDE-BC05-1DB92FEAEFF3Q35149475-7A072AB6-E716-4766-A4FE-EBDCF3F8E56DQ35169003-790F548F-91E6-40F8-8C15-3EC3550EED51
P2860
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Once-daily dolutegravir versus ...... on-inferiority SPRING-2 study.
@en
Once-daily dolutegravir versus ...... on-inferiority SPRING-2 study.
@nl
type
label
Once-daily dolutegravir versus ...... on-inferiority SPRING-2 study.
@en
Once-daily dolutegravir versus ...... on-inferiority SPRING-2 study.
@nl
prefLabel
Once-daily dolutegravir versus ...... on-inferiority SPRING-2 study.
@en
Once-daily dolutegravir versus ...... on-inferiority SPRING-2 study.
@nl
P2093
P50
P1433
P1476
Once-daily dolutegravir versus ...... on-inferiority SPRING-2 study.
@en
P2093
Anita Rachlis
Carlo Torti
Clare Brennan
Daniel Podzamczer
David Margolis
Francois Raffi
Hans-Jürgen Stellbrink
Mark Bloch
SPRING-2 Study Group
Sherene Min
P304
P356
10.1016/S0140-6736(12)61853-4
P407
P577
2013-01-08T00:00:00Z